Ascletis' swift surge into obesity continues with competitive oral GLP-1 data
Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. The Chinese biotech ticked the publication of multiple ascending dose data off its to-do list Wednesday, linking its oral GLP-1 prospect to 6.3% mean body weight loss after 28 days.
Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. The Chinese biotech ticked the publication of multiple ascending dose data off its to-do list Wednesday, linking its oral GLP-1 prospect to 6.3% mean body weight loss after 28 days.
